Livou Group (000513.SZ) lyconchitazumab injection was included in the priority review and approval process

Zhitong Finance App News, Lizhu Group (000513.SZ) announced that the company's holding subsidiary, Zhuhai Lizhudan Antibiotic Technology Co., Ltd. (“Lizumab”) and Beijing Xinkanghe Biomedical Technology Co., Ltd., was included in the publicity list of varieties to be prioritized by the Drug Evaluation Center of the State Drug Administration on December 26, 2025; after the publicity period expires, it has been included in the list of priority review varieties according to the information disclosed on the website of the Drug Evaluation Center of the State Drug Administration Approval process.